Ajanta Pharma (532331) Stock Overview
A pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
532331 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ajanta Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,523.00 |
| 52 Week High | ₹3,115.00 |
| 52 Week Low | ₹2,022.05 |
| Beta | 0.21 |
| 1 Month Change | 4.73% |
| 3 Month Change | -5.95% |
| 1 Year Change | -11.79% |
| 3 Year Change | 102.13% |
| 5 Year Change | 147.53% |
| Change since IPO | 15,668.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532331 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.1% | 2.3% | 1.1% |
| 1Y | -11.8% | -0.1% | 5.4% |
Return vs Industry: 532331 underperformed the Indian Pharmaceuticals industry which returned -0.6% over the past year.
Return vs Market: 532331 underperformed the Indian Market which returned 5.3% over the past year.
Price Volatility
| 532331 volatility | |
|---|---|
| 532331 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: 532331 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532331's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 9,628 | Yogesh Agrawal | www.ajantapharma.com |
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management.
Ajanta Pharma Limited Fundamentals Summary
| 532331 fundamental statistics | |
|---|---|
| Market cap | ₹315.12b |
| Earnings (TTM) | ₹9.74b |
| Revenue (TTM) | ₹49.73b |
Is 532331 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532331 income statement (TTM) | |
|---|---|
| Revenue | ₹49.73b |
| Cost of Revenue | ₹12.06b |
| Gross Profit | ₹37.67b |
| Other Expenses | ₹27.93b |
| Earnings | ₹9.74b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 77.96 |
| Gross Margin | 75.75% |
| Net Profit Margin | 19.58% |
| Debt/Equity Ratio | 4.7% |
How did 532331 perform over the long term?
See historical performance and comparisonDividends
Does 532331 pay a reliable dividends?
See 532331 dividend history and benchmarks| Ajanta Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Nov 10 2025 |
| Dividend Pay Date | Dec 03 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 18 days |
Does 532331 pay a reliable dividends?
See 532331 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 04:57 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ajanta Pharma Limited is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| null null | Asian Markets Securities Private Limited |